-
NovoCure Limited NASDAQ:NVCR Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Location: Forum, Saint Helier, JE2 4UF, Jersey | Website: www.novocure.com | Industry: Surgical and Medical Instrument Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.565B
Cash
959.9M
Avg Qtr Burn
-9.369M
Short % of Float
5.48%
Insider Ownership
9.63%
Institutional Own.
87.47%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Optune Lua Details Non-small cell lung carcinoma | Approved Update | |
Optune Gio® w/ radiation therapy & temozolomide (TMZ) Details Glioblastoma, Cancer | Phase 3 Data readout | |
Immune checkpoint inhibitors or docetaxel w/ NovoTTF-200T Details Non-small cell lung carcinoma | Phase 3 Update | |
Stereotactic radiosurgery (SRS) w/ NovoTTF-200M Details Brain metastases | Phase 3 Update | |
Paclitaxel w/ NovoTTF-100L(O) Details Ovarian cancer | Phase 3 Update | |
Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T Details Pancreatic cancer | Phase 3 Update | |
Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T Details Pancreatic cancer, Cancer | Phase 2 Data readout |